Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
      QxMD      Google Scholar   
Citation:
Leuk Lymphoma vol 57 (10) 2298-306
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Wendy Stock is corresponding author. For submission to Haematologica.
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
6
Parents:
431   2156  
Children:
None
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA032291, U10 CA180861, U10 CA077658, U10 CA180835, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA059518, U10 CA180850, U10 CA101140, U10 CA041287, U10 CA180882, P30 CA016058, P50 GM115279  
Corr. Author:
 
Authors:
                         
Networks:
CA043, LAPS-IL057, LAPS-MA036, LAPS-OH007   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-9665, CALGB-10001
Phases:
2, N/A
Keywords:
Lymphoid leukemia, Prognostication, Drug resistance, Transcription factor changes